Please use this identifier to cite or link to this item:
Title: Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft.
Austin Authors: McClelland, Julia;Wong, Eric ;Grigg, Andrew P 
Affiliation: Clinical Haematology
Issue Date: Feb-2023
Date: 2022
Publication information: Leukemia & Lymphoma 2023; 64(2)
Abstract: Cyclosporine is an immunosuppressive agent to prevent acute graft versus host disease (GVHD) in patients undergoing a stem cell allograft. It has a narrow therapeutic range, and its metabolism can be affected by posaconazole, commonly used as antifungal prophylaxis post allograft. There is limited evidence on the optimal oral cyclosporine starting dose in this setting. A delicate balance is required in dose adjustments to avoid toxic levels while maintaining sufficient drug concentrations to prevent GVHD. We undertook a retrospective audit of 28 patients undergoing their first allograft who received posaconazole and commenced on a starting oral cyclosporine dose of 2 mg/kg twice daily. Our key findings were that this starting dose was too high, with all patients experiencing at least one toxicity and an overall low incidence of GVHD.
DOI: 10.1080/10428194.2022.2142054
Journal: Leukemia & Lymphoma
Start page: 1
End page: 5
PubMed URL: 36368718
ISSN: 1029-2403
Type: Journal Article
Subjects: Transplantation
drug toxicity
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.